Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Watson aims for August launch of EC

This article was originally published in The Tan Sheet

Executive Summary

The maker of the just-approved Next Choice emergency contraceptive, a generic of Teva's Plan B (levonorgestrel), applies to make the drug available for nonprescription sale upon the expiration of Teva's market exclusivity Aug. 24. A spokeswoman said June 29 that Watson Pharmaceuticals is confident FDA will approve the Next Choice nonprescription application, but does not know whether the decision will come before Plan B loses exclusivity. FDA likely will apply to non-Rx levonorgestrel generics the same age restriction on pharmacy-only sales it imposed on Plan B (1"The Tan Sheet" June 29, 2009). Watson reserves the right to later seek universal OTC sales status, the spokeswoman said

You may also be interested in...



Generic Rx Plan B Approval Points To Possible OTC Equivalents In Near Future

FDA's approval of a generic prescription-only Plan B makes a nonprescription generic of the emergency contraceptive likely, potentially as early as August

Teva Concedes On US Gimoti ANDA, Voiding 180-Day Exclusivity

Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.

Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel